✦ LIBER ✦

A phase II study of Erbitux (IMC-C225), an Epidermal Growth Factor Receptor (EGFR) blocking ntibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced Non-Small Cell Lung Cancer (NSCLC)

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

53 A phase I study of epidermal growth f

✍ C. Bokemeyer; C. Kollmannsberger; M. Schittenhelm; F. Honecker; H.J. Ahrens; J. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 334 KB

A phase II study of docetaxel and vinore

✍ J Bennouna; A Monnier; A Rivière; B Milleron; E Lemarie; V Trillet-Lenoir; K Sou 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 97 KB

Prospective Phase II Study of Gefitinib

✍ Inoue, A. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 262 KB

55 Randomized phase II clinical trial of

✍ R. Rosell; R. Ramlau; A. Szczesna; C. Daniel; M. Bertrand; R. Garcia-Arroyo; K. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 168 KB

O-245 Randomized phase II clinical trial

✍ Rosell, Rafael; Constenla, Manuel; Kolb, Rainer; Pfeiffer, Wolfang; O'Bryne, Ken 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 178 KB

Docetaxel–carboplatin chemotherapy combi

✍ Fischer, J.R.; Griesinger, F.; Fink, T.; Salm, T.; Marseille, A.; Wolf, M. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 271 KB